[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jason Ahee, M.D.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100304506","phase-2-safety-and-efficacy-of-intracameral-zimoxin-for-prevention-of-endophthalmitis-after-cataract-surgery-100304506",false,"NCT03244072","Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery","Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery","Inclusion Criteria:\n\n* visually significant cataracts\n\nExclusion Criteria:\n\n* allergy to fluoroquinolones, cobalamin (B12)",true,"ALL","40 Years",{"count":20,"type":21},60000,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis",[28],"Endophthalmitis","NOT_YET_RECRUITING","2025-09-21",{"date":32,"type":33},"2025-09-25","ACTUAL",{"date":35,"type":21},"2026-06-01",{"date":37,"type":21},"2031-10",{"name":39,"class":40},"Jason Ahee, M.D.","INDUSTRY",""]